Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo.

Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo.

Background: Achieving a functional or sterilizing cure for HIV will require identification of therapeutic interventions that reduce HIV reservoir size in infected individuals. Proteasome inhibitors, such as ixazomib, impact multiple aspects of HIV biology including latency, transcription initiation,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Nathan W Cummins, Jason Baker, Rana Chakraborty, Patrick G Dean, Enrique Garcia-Rivera, Ashton Krogman, Shaji Kumar, Yury V Kuzmichev, Gregory M Laird, Alan Landay, Mathias Lichterfeld, Maryam Mahmood, Jeffrey Martinson, Mark Maynes, Sekar Natesampillai, Vincent Rajkumar, Yelizaveta Rassadkina, Kristen D. Ritter, Christina G Rivera, Stacey A Rizza, Krupa Subramanian, Aaron J Tande, Elizabeth R Wonderlich, Jennifer A Whitaker, John Zeuli, Andrew D Badley
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
HIV
Latent reservoir
Proteasome inhibitor
Ixazomib
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/9bcbc1806c0c4535bde930e29c873a95
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/9bcbc1806c0c4535bde930e29c873a95

Ejemplares similares